Stuart M. Cable

Stuart M. Cable

Partner Chair, M&A and Corporate Finance Tech | Life Sciences
Stuart M. Cable

Stuart Cable represents as outside general counsel public and private companies involved in the life sciences and technology sectors.

He currently serves as the chair of the M&A and Corporate Finance practices for the firm’s Technology and Life Sciences business units. He previously served as chair of the firm’s Corporate Department, as chair of its Hiring Committee, as chair of its Incubator, and as a member of the firm's Executive and Allocations Committees.

Areas of Practice
Domaines D’Expertise





Mr. Cable counsels boards of directors and management teams on corporate governance, mergers and acquisitions, and disclosure and securities law matters.

Mr. Cable represents buyers, sellers and investment banks in his M&A practice. Representative M&A transactions in the past five years include the sale of Onyx Pharmaceuticals to Amgen ($10.4 billion), the sale of Eloqua to Oracle ($1 billion), the 2015 majority sale of Foundation Medicine to Roche ($1 billion) and the subsequent (2018) negotiated tender for the public stub by Roche ($2.4 billion), the sale of Idenix to Merck ($3.8 billion), the sale of Pharmacyclics to AbbVie ($21 billion), the sale of Xoom to PayPal ($1 billion), the private company sale of Stemcentrix to Abbvie ($5.8 billion), the sale of Opower to Oracle ($600 million), the acquisition of NXP by Qualcomm ($47 billion), the Reverse Morris Trust merger of a division of Citrix into LogMeIn ($2 billion), the cross border private company acquisitions of Euticals ($358 million – Italy) and Gadea ($174 million – Spain) by AMRI, the acquisition of Auspex by Teva Pharmaceuticals ($3.5 billion), the private company acquisition and subsequent 2018 sale of Cord Blood Registry by AMAG Pharmaceuticals.

In 2017, Mr. Cable represented Neustar in its sale to Golden Gate ($2.9 billion), Lionbridge in its sale to HIG ($400 million), AMRI in its sale to Carlyle and GTCR ($1.9 billion), PAREXEL in its sale to Pamplona ($5 billion), and the cross border sale of inviCRO to Konica Minolta (Japan) ($300 million).

Mr. Cable is retained from time to time to represent "independent" or "special" committees of the Board of Directors, most recently representing the independent committees of Sprint in the 2018 Sprint/T-Mobile transaction ($26 billion), and Globalstar in the 2018 Globalstar/FiberLight transaction ($1.65 billion). In the course of his career, Mr. Cable has negotiated and executed over 300 M&A transactions.

Mr. Cable serves regularly as counsel to issuers and underwriters in IPOs recently representing J.P. Morgan in the cross-border IPO of Trivago, Morgan Stanley in the 2018 IPO of Evelo and Rubius in its pending 2018 IPO.

Mr. Cable also represents tech and life sciences companies in complex minority strategic transactions including KIND in its 2018 partnership with Mars, Cornerstone onDemand in its 2018 $300 million convertible debt PIPE with Silver Lake and Microsoft, and PTC in its 2018 $1 billion common stock PIPE and strategic partnership with Rockwell. Mr. Cable also represented Keryx in its announced 2018 merger of equals transaction with Akebia.

Mr. Cable periodically represents public companies in connection with highly confidential “activist” matters, including the successful negotiation of "Cooperation" Agreements with Elliott Management on behalf of Cognizant and Citrix.

Mr. Cable also represents a number of private venture backed life sciences companies in Board governance, collaboration transactions, crossover financings and IPOs (including Moderna, Rubius and Yumanity).


Mr. Cable serves as a member of the President's Leadership Council at Dartmouth College and as chairman emeritus of the Buckingham Browne & Nichols School. He also served for more than a decade as a member of the Board of Fellows of Harvard Medical School.

Mr. Cable leads the firm’s Pro Bono efforts on behalf of Camp Harbor View, a summer enrichment program for Boston’s youth founded by Jack Connors.

Mr. Cable recently represented Atul Gawande and his not for profit Ariadne on a Pro Bono basis in the formation of a new not for profit healthcare delivery entity supported by generous contributions from Amazon, Berkshire Hathaway and J.P. Morgan.

Mr. Cable is also a member of the Goodwin Pro Bono team servicing the Boston Red Sox Foundation where Mr. Cable advises on Board and governance matters.


Mr. Cable is annually ranked in Chambers USA: America’s Leading Lawyers for Business (Corporate/M&A – Band 1), Chambers Global: The Leading Lawyers for Business (Corporate/M&A) and U.S. News-Best Lawyers (Corporate Law). Global M&A Network has named him one of the world’s top 50 M&A lawyers, recognizing his work advising Onyx Pharmaceuticals in its $10.4 billion purchase by Amgen – a transaction named 2014 Global Major Markets Life Sciences Deal of the Year. Mr. Cable also was recognized by the Financial Times in both 2015 and 2016, winning its award for Innovative Deal of the Year in advising Foundation Medicine in its $1 billion majority purchase by Roche, and in 2016 advising Citrix in its $2.6 billion Reverse Morris Trust merger with LogMeIn. In 2016, Mr. Cable was recognized by LMG as Life Sciences Transaction Attorney of the Year. In 2017, Mr. Cable was recognized by Law360 as Life Sciences MVP.

In The News









J.D., 1979
Columbia Law School

(Harlan Fiske Stone Scholar)

M.B.A., 1976
Tuck School of Business at Dartmouth
A.B., 1975
Dartmouth College

(magna cum laude)

Get In Touch
German Translation
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique